02137 騰盛博藥－Ｂ
按盤價 
1.400 +0.010 (+0.719%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 資產回報率 (%) | -8.789% | -17.212% | -5.306% | -13.830% | -170.662% |
| 股東資金回報率 (%) | -8.847% | -17.596% | -5.538% | -14.816% | -518.984% |
| 資本運用回報率 (%) | -9.566% | -19.328% | -5.690% | -15.313% | -125.003% |
邊際利潤分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | -- | N/A | -- | -- | N/A |
| 未計利息、稅項、折舊及攤銷前利潤率 (%) | -1429.739% | N/A | -44769.044% | -986.135% | N/A |
| 稅前邊際利潤率 (%) | -1194.125% | N/A | -29881.686% | -948.710% | N/A |
| 純利率 (%) | -1196.582% | N/A | -28335.332% | -938.116% | N/A |
變現能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流動比率 (X) | 60.734 X | 31.182 X | 22.109 X | 13.430 X | 12.162 X |
| 速動比率 (X) | 60.734 X | 31.182 X | 22.109 X | 13.430 X | 12.162 X |
財務槓桿分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 總負債 / 總資產比率 (%) | 1.534% | 3.715% | 3.936% | 6.909% | 8.319% |
| 總債項 / 總資產比率 (%) | 0.378% | 1.699% | 0.099% | 0.373% | 0.598% |
| 淨債項 / 總資產比率 (%) | -25.340% | -35.372% | -15.211% | -34.728% | -78.453% |
| 總債項 / 股東資金比率 (%) | 0.376% | 1.731% | 0.101% | 0.396% | 0.647% |
| 長期債項 / 股東資金比率 (%) | 0.164% | 0.870% | 0% | 0.099% | 0.378% |
| 淨債項 / 股東資金比率 (%) | -25.168% | -36.033% | -15.598% | -36.872% | -84.761% |
| 淨現金 / (債項) ($) | 5.98億 | 9.57億 | 4.86億 | 11.78億 | 28.33億 |
| 每股淨現金 / (債項) ($) | 0.829 | 1.309 | 0.667 | 1.620 | 3.934 |
| 總債項 / 資本運用比率 (%) | 0.384% | 1.749% | 0.103% | 0.400% | 0.649% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
營運效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存貨周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 應收貿易帳周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 應付貿易帳周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 備註： | 即時報價更新時間為31/03/2026 10:08 |
| 港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
| 股東應佔溢利/(虧損) (千) | RMB -222,624 |
| 增長率 | -56.190% |
| 每股盈利/(虧損) | RMB -0.310 |
| 每股帳面資產淨值 (¥) | RMB 3.294 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
